Search results for " Follow-up"

showing 10 items of 229 documents

Transition Care in Anorexia Nervosa Through Guidance Online from Peer and Carer Expertise (TRIANGLE): Study Protocol for a Randomised Controlled Trial

2017

TRIANGLE is a multicentre trial investigating whether the addition of a novel intervention for patients and carers (ECHOMANTRA) to treatment as usual (TAU) improves outcomes for people with anorexia nervosa (AN). ECHOMANTRA is based on the cognitive interpersonal model of AN and includes assessments, workbooks, videos, online groups and joint Skype sessions for patients and carers. People receiving intensive hospital treatment (N = 380) will be randomised to TAU or TAU plus ECHOMANTRA. Participants will be assessed over an 18-month period following randomisation. The primary outcome is patient psychological well-being at 12 months postrandomisation. Secondary outcomes include (i) patient's …

Adultanorexia nervosa carer skills guided self-help skills sharing Adult Anorexia Nervosa Caregivers Follow-Up Studies Humans Internet Peer Group Quality of Life Research Design Transitional Care Treatment OutcomeInternetanorexia nervosa; carer skills; eating disorders; guided self-help; skills sharingTransitional Careeating disorderscarer skillsPeer Groupguided self-helpanorexia nervosaHTreatment OutcomeCaregiversResearch DesignSettore M-PSI/08 - Psicologia ClinicaQuality of LifeHumansskills sharingFollow-Up Studies
researchProduct

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience

2019

Teriflunomide (TRF) and Dimethyl fumarate (DMF) are licensed drugs for relapsing-remitting Multiple Sclerosis (RRMS). We aimed to compare the rate and the time to discontinuation among persons with RRMS (pwRRMS), newly treated with TRF and DMF. A retrospective study on prospectively collected data was performed in nine tertiary MS centers, in Italy. The 24-month discontinuation rate in the two cohorts was the primary study outcome. We also assessed the time to discontinuation and reasons of therapy withdrawn. Discontinuation of TRF and DMF was defined as a gap of treatment ≥ 60 days. A cohort of 903 pwRRMS (316 on TRF and 587 on DMF) was analyzed. During 24 months of follow-up, pwRRMS on TR…

Adultmedicine.medical_specialtyDiscontinuation rateTime FactorsToluidinesPopulationHydroxybutyratesRelapsing-RemittingDimethyl fumarateMultiple sclerosis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideNitrilesTeriflunomidemedicineHumansMultiple sclerosi030212 general & internal medicineeducationRetrospective Studieseducation.field_of_studyDimethyl fumaratebusiness.industryProportional hazards modelMultiple sclerosisDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Neurology; Neurology (clinical)Real-lifeRetrospective cohort studyMiddle Agedmedicine.diseaseDiscontinuationchemistryItalyNeurologyCrotonatesCohortDimethyl fumarate; Discontinuation rate; Multiple sclerosis; Real-life; Teriflunomide; Adult; Crotonates; Dimethyl Fumarate; Follow-Up Studies; Humans; Immunosuppressive Agents; Italy; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Retrospective Studies; Time Factors; ToluidinesNeurology (clinical)business030217 neurology & neurosurgeryImmunosuppressive AgentsFollow-Up Studies
researchProduct

Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission.…

2019

Abstract To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as first-line therapy, in inducing remission in naïve Adult-onset Still's disease (AOSD) patients compared with low dosage of CCSs, after 6 months. To further evaluate the rate of patients maintaining the remission and the rate of CCSs discontinuation, after additional 12 months of follow-up. A retrospective evaluation of patients prospectively followed was designed to compare the rate of clinical remission in naïve AOSD patients treated with high dosages of CCSs (0.8–1 mg/kg/day of prednisone-equivalent) or low dosage of CCSs (0.2–0.3 mg/kg/day of prednisone-equivalent), after 6 months. An add…

Adult-OnsetMalePediatricsAdult-onset Still's diseaseDiseaseAdrenal Cortex Hormonecorticosteroids0302 clinical medicinemonocyclic patternAdrenal Cortex HormonesRetrospective StudieMedicine030212 general & internal medicineProspective StudiesProspective cohort studyRemission InductionDisease ManagementGeneral MedicineMiddle AgedTreatment OutcomeHigh dosage030220 oncology & carcinogenesisFemaleDrugStill's Disease Adult-OnsetResearch ArticleHumanAdultcorticosteroidmedicine.medical_specialtyLow dosageObservational StudyAdult-onset Still's diseaseFollow-Up StudieDose-Response Relationship03 medical and health sciencesremissionAdult-onset Still's disease; corticosteroids; first-line therapy; monocyclic pattern; remission; Adrenal Cortex Hormones; Adult; Disease Management; Dose-Response Relationship Drug; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Retrospective Studies; Still's Disease Adult-Onset; Treatment Outcomefirst-line therapyHumansRetrospective StudiesDose-Response Relationship Drugbusiness.industry6900Retrospective cohort studyStill's DiseaseFirst line treatmentSettore MED/16 - ReumatologiaProspective StudieMethotrexateObservational studybusinessFollow-Up Studies
researchProduct

FISSIT (Fistula Surgery in Italy) study: A retrospective survey on the surgical management of anal fistulas in Italy over the last 15 years

2021

Background: Surgical treatment of anal fistulas is still a challenge. The aims of this study were to evaluate the adoption and healing rates for the different surgical techniques used in Italy over the past 15 years. Methods: This was a multicenter retrospective observational study of patients affected by simple and complex anal fistulas of cryptoglandular origin who were surgically treated in the period 2003–2017. Surgical techniques were grouped as sphincter-cutting or sphincter-sparing and as technology-assisted or techno-free. All patients included in the study were followed for at least 12 months. Results: A total of 9,536 patients (5,520 simple; 4,016 complex fistulas) entered the stu…

Anal fistulaMalemedicine.medical_specialtyCure rateFistulaSettore MED/18 - CHIRURGIA GENERALEAnal CanalAnal Canal; Fecal Incontinence; Female; Follow-Up Studies; Humans; Incidence; Italy; Male; Middle Aged; Population Surveillance; Postoperative Complications; Rectal Fistula; Retrospective Studies; ForecastingFistulotomyFollow-Up StudiePostoperative ComplicationsRetrospective surveyRetrospective StudiemedicineHumansRectal FistulaAnal fistulaSurgical treatmentRetrospective Studiesanorectal fistulabusiness.industryIncidenceRetrospective cohort studyMiddle Agedmedicine.diseaseSurgerySettore MED/18ItalyPopulation SurveillanceSurgeryFemalePostoperative ComplicationbusinessFecal IncontinenceHumanFollow-Up StudiesForecasting
researchProduct

Aortic valve disease: follow-up of a group of patients undergone to aortic valve replacement.

2007

Aortic valve replacement long term follow-up
researchProduct

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/I…

2016

Abstract Background: mTOR inhibition has been shown to be effective in various subtypes of malignant lymphomas (Smith et al, JCO 2010). Furthermore, in relapsed MCL a phase III trial demonstrated superiority of Temsirolimus to chemotherapy. Although novel treatment options as Ibrutinib have changed the treatment landscape for MCL, no curative potential could be shown for this approach and novel concepts continue to be needed. Several trials provided promising results when Temsirolimus is combined with agents like Rituximab (Ansell et al, Lancet Oncology 2011) or chemoimmunotherapy, as shown in part I (phase I) of the reported trial (Hess, Leukemia, 2015). We now report the final analysis of…

BendamustineOncologymedicine.medical_specialtyImmunologyFollicular lymphoma02 engineering and technologyBiochemistry03 medical and health sciences020210 optoelectronics & photonics0302 clinical medicineMedian follow-upChemoimmunotherapyInternal medicine0202 electrical engineering electronic engineering information engineeringMedicinebusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimenTemsirolimusRegimen030220 oncology & carcinogenesisRituximabbusinessmedicine.drugBlood
researchProduct

Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in "ultra High-risk" CLL: Final Results from the CLL2O Phase…

2014

CLL with deletion 17p (17p-) or refractory to fludarabine (F)-based regimens is characterized by poor prognosis. The cooperative French/German CLL2O study aimed at achieving deep and durable response in this population by combining alemtuzumab (A) and dexamethasone (D) induction, followed by consolidation with A maintenance or allogeneic stem-cell transplantation (allo-SCT). Induction treatment consisted of subcutaneous A (30mg, 3x weekly) combined with oral D (40 mg days 1-4 and 15-18), both at 28 day cycles, and prophylactic pegfilgrastim 6 mg on days 1 and 15. If at least SD was achieved after 3 cycles, consolidation was scheduled with either allo-SCT or A maintenance (30mg every 2 weeks…

Bendamustineeducation.field_of_studymedicine.medical_specialtybusiness.industryImmunologyPopulationPhases of clinical researchCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologySurgeryTransplantationMedian follow-upInternal medicinemedicineAlemtuzumabbusinesseducationPegfilgrastimmedicine.drug
researchProduct

Quality of life following urinary diversion: Orthotopic ileal neobladder versus ileal conduit. A multicentre study among long-term, female bladder ca…

2019

Abstract Introduction Women undergoing radical cystectomy (RC) followed by urinary diversion (UD) for bladder cancer experience a substantial reduction in health-related quality of life (HRQOL). At present, studies comparing long-term QOL outcomes for different UD methods, needed to inform evidence-based choices of bladder reconstruction for female patients, are sparse. Our objective was to compare two common UD methods in terms of their HRQOL outcomes in women. Materials and methods We retrospectively analysed HRQOL in 73 consecutive female bladder cancer patients having undergone orthotopic ileal neobladder (IONB, N = 24) or ileal conduit (IC, N = 49) following RC between 2007 and 2013 in…

Bladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; Women;Time Factorsmedicine.medical_treatment030232 urology & nephrologyUrinary DiversionBladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; Women; Adult; Aged; Aged 80 and over; Cancer Survivors; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Ileum; Italy; Middle Aged; Surveys and Questionnaires; Survival Rate; Time Factors; Urinary Bladder Neoplasms; Urinary Diversion; Quality of Life; Urinary Reservoirs Continent; Surgery; Oncology0302 clinical medicineCancer SurvivorsQuality of lifeSurveys and QuestionnairesOrthotopic neobladder80 and overSurveys and QuestionnaireStage (cooking)Aged 80 and overSettore MED/24 - UROLOGIABladder cancerUrinary Reservoirs ContinentGeneral MedicineMiddle AgedhumanitiesSurvival RateIleal conduitItalyOncology030220 oncology & carcinogenesisUrinary Bladder NeoplasmFemaleCancer SurvivorUrinary ReservoirsHumanQuality of lifeAdultmedicine.medical_specialtyTime FactorFollow-Up StudieCystectomy03 medical and health sciencesIleumInternal medicinemedicineHumansWomenPathologicalAgedCross-Sectional StudieBladder cancerbusiness.industryUrinary diversionCancermedicine.diseaseRadiation therapyRadical cystectomyContinentCross-Sectional StudiesBladder cancer; Ileal conduit; Orthotopic neobladder; Quality of life; Radical cystectomy; WomenUrinary Bladder NeoplasmsSurgerybusinessFollow-Up StudiesEuropean Journal of Surgical Oncology
researchProduct

Effects of Polyphenol, Measured by a Biomarker of Total Polyphenols in Urine, on Cardiovascular Risk Factors After a Long-Term Follow-Up in the PREDI…

2016

Several epidemiological studies have shown an inverse association between the consumption of polyphenol-rich foods and risk of cardiovascular diseases. However, accuracy and reliability of these studies may be increased using urinary total polyphenol excretion (TPE) as a biomarker for total polyphenol intake. Our aim was to assess if antioxidant activity, measured by a Folin-Ciocalteu assay in urine, is correlated with an improvement in cardiovascular risk factors (blood pressure and serum glucose, cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride concentrations) in an elderly population at high risk. A longitudinal study was performed with 573 participants (aged 67.3 ± 5.9) f…

Blood GlucoseMale0301 basic medicineAgingSistema cardiovascular -- MalaltiesBlood PressureUrine030204 cardiovascular system & hematologyBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicineRisk FactorsPolyphenols in urineLongitudinal StudiesCardiovascular risk factorsAged 80 and overBioquímica y tecnologíalcsh:CytologyConfoundingBiochemical markersGeneral MedicineMiddle AgedMetabolismeBiochemistry and technologyCholesterolCardiovascular diseasesCardiovascular DiseasesPolifenolsMarcadors bioquímicsBiomarker (medicine)FemaleColesterolResearch Articlemedicine.medical_specialtyArticle SubjectUrinary systemNutritional StatusBioquímica i biotecnologiaExcretion03 medical and health sciencesMediterranean cooking:Ciencias de la Salud::Medicina preventiva [Materias Investigacion]Medical statisticsInternal medicineCuina mediterràniamedicineMortalitatHumansFood consumptionlcsh:QH573-671MortalityLong-term follow-upTriglyceridesAged030109 nutrition & dieteticsTriglycerideCholesterolbusiness.industryMalalties cardiovascularsCholesterol HDLPolyphenolsPREDIMED studyCholesterol LDLFeeding BehaviorBiomarkerEffects of PolyphenolCell BiologyPressió arterial1942-0900Blood pressureMetabolismchemistryMultivariate AnalysisLinear ModelsbusinessEstadística mèdicaConsum d'alimentsBiomarkersFollow-Up StudiesOxidative Medicine and Cellular Longevity
researchProduct

Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controv…

2016

Contains fulltext : 171468pub.pdf (Publisher’s version ) (Open Access) Primary treatment of rectal cancer was the focus of the second St. Gallen European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Cancer Conference. In the context of the conference, a multidisciplinary international expert panel discussed and voted on controversial issues which could not be easily answered using published evidence. Main topics included optimal pretherapeutic imaging, indication and type of neoadjuvant treatment, and the treatment strategies in advanced tumours. Here we report the key recommendations and summarise the related evidence. The treatment strategy for localised rect…

Cancer ResearchStagingColorectal cancermedicine.medical_treatmentNeoplasias Gastrointestinais030230 surgerySYNCHRONOUS LIVER METASTASESImagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]SHORT-COURSE RADIOTHERAPYRectal cancerNeoadjuvant therapyGastrointestinal NeoplasmsRectal Neoplasms/drug therapyCombination chemotherapyChemoradiotherapyCombined Modality TherapyTotal mesorectal excisionNeoadjuvant TherapyEuropeNeoplasias do Recto/quimioterapiaOncology030220 oncology & carcinogenesisMEDIAN FOLLOW-UPLife Sciences & BiomedicineDiagnostic Imagingmedicine.medical_specialtyAntineoplastic AgentsLOCAL RECURRENCERisk AssessmentCOURSE PREOPERATIVE RADIOTHERAPY03 medical and health sciencesmedicineHumansGastrointestinal cancerOncology & CarcinogenesisRadiochemotherapyNeoplasm StagingScience & TechnologyRadiotherapyRectal Neoplasmsbusiness.industryGeneral surgeryTOTAL MESORECTAL EXCISIONCancerRANDOMIZED PHASE-IIImedicine.diseaseSurgeryRadiation therapySurgerybusiness1112 Oncology And CarcinogenesisChemoradiotherapyPOSTOPERATIVE CHEMORADIOTHERAPY
researchProduct